Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

Currently viewing trials
(Last updated: November 13, 2019)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2

Chemotherapy

Hormone Therapy

Radiation Oncology

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Genetics/Family History

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Support/Education

Surveys/Interviews/Registries

1

NEAREST SITE: 2567 miles
Memorioal Sloan Kettering Cancer Center
New York,NY

VISITS: Visits weekly for 3 weeks, then once a month thereafter, ongoing

PHASE: I-II

NCT ID: NCT03344536

Debio 1347 plus Faslodex for HR+ Metastatic Breast Cancer

A Phase Ib/II Study of Debio 1347 Plus Fulvestrant in Patients With FGFR-Amplified Endocrine Receptor Positive Metastatic Breast Cancer Scientific Title

Purpose
To investigate the safety and effect (good and bad) of using an experimental targeted therapy called Debio 1347 along with Faslodex to treat HR+ metastatic breast cancer.
Who is this for?
Women with estrogen receptor positive metastatic (stage IV) breast cancer whose tumor tests positive for FGFR (fibroblast growth factor receptor).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Debio 1347, by mouth, daily, ongoing </li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, weekly for 3 weeks, then once a month thereafter</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">If you are premenopausal, you will also receive goserelin (Zoladex®)</i></p>
  • <p class="seamTextPara"> Debio 1347 works by targeting the FGFR protein. </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a hormone therapy used to treat hormone-sensitive metastatic breast cancer. </li> <li class="seamTextUnorderedListItem">If you are premenopausal, you will also be treated with goserelin (Zoladex®).</li> </ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03344536' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2500' target='_blank'>Journal of Clinical Oncology: Debio 1347</a> </li></ul>
See more